Skip to main content
AGMB
NASDAQ Life Sciences

Agomab Doses First Patient in Global Phase 2b NOV-ERA Study of Ontunisertib in Fibrostenosing Crohn's Disease

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$8.81
Mkt Cap
$447.664M
52W Low
$7.97
52W High
$17.82
52W Position info
11% above low
Off High info
51% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

AGMB is trading near its 52-week low of $7.97 (11% above the low).

Summary

Agomab announced the first patient dosed in its global Phase 2b NOV-ERA study of ontunisertib in fibrostenosing Crohn's disease, triggering a €7 million milestone payment to former Origo Biopharma shareholders.


Key Events · Product Development and Regulatory · AGMB

  • First Patient Dosed in Phase 2b NOV-ERA Study

    The first patient has been dosed in the global Phase 2b NOV-ERA study of ontunisertib in fibrostenosing Crohn's disease, a condition with no approved anti-fibrotic therapies.

  • Study Design and Endpoints

    NOV-ERA will enroll approximately 320 patients randomized 1:1:1:1 to three ontunisertib dose levels (400/200/100 mg BID) or placebo for 52 weeks, with endoscopic passability at Week 24 as the primary endpoint.

  • €7M Milestone Payment Triggered

    Study initiation triggers a €7 million payment to former Origo Biopharma shareholders under the 2021 acquisition, bringing total milestone payments to €10 million of a possible €20 million.

  • Builds on Positive Phase 2a Data

    The Phase 2b initiation follows positive Phase 2a STENOVA results and long-term open-label extension safety data announced earlier in October 2026, supporting the 400 mg BID arm.


Analysis · AGMB · Life Sciences

Ontunisertib has advanced into a global Phase 2b trial for fibrostenosing Crohn's disease, a condition with no approved anti-fibrotic therapies. The study will enroll approximately 320 patients across three dose levels with a 52-week treatment period, and the primary endpoint is endoscopic passability at Week 24. This milestone triggers a €7 million payment to former Origo Biopharma shareholders, bringing total milestone payments to €10 million of a possible €20 million. The initiation follows positive Phase 2a STENOVA data and long-term open-label extension results announced earlier this month, and it positions ontunisertib as a potential first-in-class targeted anti-fibrotic treatment.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AGMB was trading at $8.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $447.7M. The 52-week trading range was $7.97 to $17.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AGMB - Latest Insights

AGMB
Oct 01, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $11.10
Real-time Price: $6.35 info
Change: -$4.75 (-43%) info
Market Cap: $313.217M info
AGMB
Sep 14, 2026, 4:48 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $12.28
Real-time Price: $6.35 info
Change: -$5.93 (-48%) info
Market Cap: $313.217M info
AGMB
Sep 14, 2026, 4:14 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $12.28
Real-time Price: $6.35 info
Change: -$5.93 (-48%) info
Market Cap: $313.217M info
AGMB
Aug 06, 2026, 4:06 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $13.50
Real-time Price: $6.35 info
Change: -$7.15 (-53%) info
Market Cap: $313.217M info
AGMB
Aug 06, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $13.50
Real-time Price: $6.35 info
Change: -$7.15 (-53%) info
Market Cap: $313.217M info